| 臺大學術典藏 |
2022-06-10T06:11:10Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
Yang S.-H.; Lin C.-C.; ZHONG-ZHE LIN; Tseng Y.-L.; Hong R.-L. |
| 臺大學術典藏 |
2022-06-10T06:11:08Z |
Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy
|
ZHONG-ZHE LIN; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L. |
| 臺大學術典藏 |
2022-05-05T09:10:38Z |
Quality of life in patients of nasopharyngeal carcinoma: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35
|
WEI-CHU CHIE; Hong R.-L.; Lai C.-C.; Ting L.-L.; Hsu M.-M. |
| 臺大學術典藏 |
2022-05-05T08:48:57Z |
Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma
|
Hong R.-L.; Ting L.-L.; Ko J.-Y.; Hsu M.-M.; Sheen T.-S.; Lou P.-J.; CHIA-CHUN WANG; Chung N.-N.; Lui L.T. |
| 臺大學術典藏 |
2022-05-05T08:48:57Z |
Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5 fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: A phase II study
|
Hong R.L.; Sheen T.S.; Ko J.Y.; Hsu M.M.; CHIA-CHUN WANG; Ting L.L. |
| 臺大學術典藏 |
2022-04-26T07:24:38Z |
A Clinicopathological Study of Cytomegalovirus Lymphadenitis and Tonsillitis and Their Association with Epstein�VBarr Virus
|
Yu S.-C.; KUAN-YIN KO; Teng S.-C.; Huang T.-C.; Lo H.-T.; Cheng C.-L.; Yao M.; Hong R.-L.; Chen C.-N.; Chen T.-C.; Yang T.-L. |
| 臺大學術典藏 |
2022-04-25T07:36:11Z |
Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; Tien F.-M.; JIA-HAU LIU; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; Kuo S.-H.; Hong R.-L.; Huang T.-C.; Yao M. |
| 臺大學術典藏 |
2022-04-21T06:51:36Z |
Early restaging whole-body 18F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma
|
Yen R.-F.; Chen, Tony Hsiu Hsi; Ting L.-L.; Tzen K.-Y.; Pan M.-H.; Hong R.-L. |
| 臺大學術典藏 |
2022-04-21T06:51:35Z |
Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma
|
Yen R.-F.; Hong R.-L.; Tzen K.-Y.; Pan M.-H.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-04-21T06:51:10Z |
The Cost-utility Analysis of 18-Fluoro-2-Deoxyglucose Positron Emission Tomography in the Diagnosis of Recurrent Nasopharyngeal Carcinoma
|
Yen R.-F.; Yen M.-F.; Hong R.-L.; Tzen K.-Y.; Chien C.-R.; Chen, Tony Hsiu Hsi |
| 臺大學術典藏 |
2022-04-15T03:14:17Z |
Clinical and functional characterization of a novel STUB1 frameshift mutation in autosomal dominant spinocerebellar ataxia type 48 (SCA48)
|
Yu S.-C.; Ko K.-Y.; SHU-CHUN TENG; Huang T.-C.; Lo H.-T.; Cheng C.-L.; Yao M.; Hong R.-L.; Chen C.-N.; Chen T.-C.; Yang T.-L. |
| 臺大學術典藏 |
2022-04-14T07:20:22Z |
Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; FENG-MING TIEN; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; Kuo S.-H.; Hong R.-L.; Huang T.-C.; Yao M. |
| 臺大學術典藏 |
2022-03-08T03:44:07Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
SHIH-HUNG YANG; Lin C.-C.; Lin Z.-Z.; Tseng Y.-L.; Hong R.-L. |
| 臺大學術典藏 |
2022-03-04T06:53:40Z |
Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate–cysteine ligase catalytic subunit in head and neck squamous cell carcinoma
|
Liu C.-W.; Hua K.-T.; Li K.-C.; Kao H.-F.; Hong R.-L.; Ko J.-Y.; Hsiao M.; Kuo M.-L.; CHING-TING TAN |
| 臺大學術典藏 |
2022-03-04T05:33:54Z |
Relation between Histological Intensity of Transforming Growth Factor-β Isoforms in Human Osteosarcoma and the Rate of Lung Metastasis
|
Yang R.-S.; CHEN-TU WU; Lin K.-H.; Hong R.-L.; Liu T.-K.; Lin K.-S. |
| 臺大學術典藏 |
2022-03-04T05:33:47Z |
Response of refractory osteosarcoma to thalidomide and celecoxib
|
Tsai Y.-C.; CHEN-TU WU; Hong R.-L. |
| 臺大學術典藏 |
2022-02-14T07:10:34Z |
A Clinicopathological Study of Cytomegalovirus Lymphadenitis and Tonsillitis and Their Association with Epstein–Barr Virus
|
SHAN-CHI YU; Ko K.-Y.; Teng S.-C.; Huang T.-C.; Lo H.-T.; Cheng C.-L.; Yao M.; Hong R.-L.; Chen C.-N.; Chen T.-C.; Yang T.-L. |
| 臺大學術典藏 |
2022-02-07T07:49:00Z |
Polatuzumab vedotin�Vbased salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang Y.-W.; Tsai X.C.-H.; Hou H.-A.; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; SUNG-HSIN KUO; Hong R.-L.; Huang T.-C.; Yao M. |
| 臺大學術典藏 |
2022-01-12T07:07:09Z |
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
|
Wang Y.-W.; Tsai X.C.-H.; HSIN-AN HOU; Tien F.-M.; Liu J.-H.; Chou W.-C.; Ko B.-S.; Chen Y.-W.; Lin C.-C.; Cheng C.-L.; Lo M.-Y.; Lin Y.-C.; Lu L.-C.; Wu S.-J.; Kuo S.-H.; Hong R.-L.; Huang T.-C.; Yao M. |
| 臺大學術典藏 |
2021-11-18T04:58:21Z |
Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5 fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: A phase II study
|
Hong R.L; Sheen T.S; JENG-YUH KO; Hsu M.M; Wang C.C; Ting L.L. |
| 臺大學術典藏 |
2021-11-18T04:58:20Z |
DNA content of nasopharyngeal carcinoma: An independent prognostic indicator
|
Hsu M.-M; Chiou C.-R; JENG-YUH KO; Sheen T.-S; Hong R.-L; Ting L.-L. |
| 臺大學術典藏 |
2021-11-18T04:58:19Z |
Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma
|
Hong R.-L; Ting L.-L; JENG-YUH KO; Hsu M.-M; Sheen T.-S; Lou P.-J; Wang C.-C; Chung N.-N; Lui L.T. |
| 臺大學術典藏 |
2021-11-18T04:58:19Z |
Factors affecting the overall survival after salvage surgery in patients with recurrent nasopharyngeal carcinoma at the primary site: Experience with 60 cases
|
Hsu M.-M; Hong R.-L; Ting L.-L; JENG-YUH KO; Sheen T.-S; Lou P.-J. |
| 臺大學術典藏 |
2021-11-18T04:58:17Z |
Recent advances in the treatment of nasopharyngeal carcinoma
|
Chang J.T.-C; JENG-YUH KO; Hong R.-L. |
| 臺大學術典藏 |
2021-11-18T04:58:17Z |
Comparison of Clinical and Molecular Surveillance in Patients with Advanced Nasopharyngeal Carcinoma after Primary Therapy: The Potential Role of Quantitative Analysis of Circulating Epstein-Barr Virus DNA
|
Hong R.-L; Lin C.-Y; Ting L.-L; JENG-YUH KO; Hsu M.-M. |
